| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/13543784.2016.1181749 |
| P698 | PubMed publication ID | 27104862 |
| P2093 | author name string | Barry H Greenberg | |
| Felice Lin | |||
| Hao A Tran | |||
| P2860 | cites work | Activation of orphan receptors by the hormone relaxin | Q24292229 |
| Epidemiology and risk profile of heart failure | Q24630778 | ||
| Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology | Q27024879 | ||
| Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase | Q27661554 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Effect of nesiritide in patients with acute decompensated heart failure | Q28242547 | ||
| Angiotensin-neprilysin inhibition versus enalapril in heart failure | Q28247091 | ||
| Haemodynamic and renal effects of urodilatin in healthy volunteers | Q54271784 | ||
| Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes | Q57628743 | ||
| Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease | Q57911462 | ||
| Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury | Q28252995 | ||
| Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study | Q28291971 | ||
| Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial | Q28300233 | ||
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy | Q28593656 | ||
| Heart disease and stroke statistics--2014 update: a report from the American Heart Association | Q29547691 | ||
| Cardiac myosin activation: a potential therapeutic approach for systolic heart failure | Q30583292 | ||
| Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group | Q30596519 | ||
| Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. | Q31383623 | ||
| Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group | Q33157410 | ||
| Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study | Q33186937 | ||
| Cardiac myosin activation part 1: from concept to clinic | Q33913192 | ||
| Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial | Q34003169 | ||
| Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report | Q34064492 | ||
| A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure | Q34106793 | ||
| Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure | Q34117227 | ||
| Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. | Q34134694 | ||
| Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction | Q34187441 | ||
| Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure | Q34207537 | ||
| Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study | Q34209528 | ||
| The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. | Q34209536 | ||
| Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial | Q34310960 | ||
| Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney diseas | Q34462504 | ||
| Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials | Q34472913 | ||
| Nonsteroidal antagonists of the mineralocorticoid receptor | Q34481103 | ||
| Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 | ||
| ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the | Q34640762 | ||
| Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes | Q34646866 | ||
| Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). | Q34682919 | ||
| Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide | Q35046881 | ||
| The natriuretic peptides in cardiovascular medicine | Q35954254 | ||
| A review of the renal and neurohormonal effects of B-type natriuretic peptide | Q36050051 | ||
| Emerging therapies for the management of decompensated heart failure: from bench to bedside | Q36686323 | ||
| C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target | Q36708991 | ||
| Urodilatin: a better natriuretic peptide? | Q36947430 | ||
| Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial | Q37094366 | ||
| Neuregulin in cardiovascular development and disease | Q37118330 | ||
| The role of Neuregulin-1beta/ErbB signaling in the heart | Q37155921 | ||
| Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics | Q37420916 | ||
| Learning from recent trials and shaping the future of acute heart failure trials | Q37531278 | ||
| Role of guanylate cyclase modulators in decompensated heart failure | Q37537154 | ||
| Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association | Q37538031 | ||
| Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation. | Q37648577 | ||
| The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy | Q37670521 | ||
| Cell death in the pathogenesis of heart disease: mechanisms and significance | Q37690704 | ||
| Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure | Q37694008 | ||
| Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics | Q37902778 | ||
| CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. | Q37911729 | ||
| Soluble guanylate cyclase: a potential therapeutic target for heart failure | Q38012596 | ||
| Serelaxin : a potential new drug for the treatment of acute heart failure | Q38215304 | ||
| Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial | Q38400549 | ||
| Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. | Q38449826 | ||
| Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial | Q38454911 | ||
| Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses | Q38500442 | ||
| Riociguat: a novel new drug for treatment of pulmonary hypertension | Q38502798 | ||
| Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. | Q39210310 | ||
| Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. | Q39305717 | ||
| G protein-coupled receptor kinase and beta-arrestin-mediated desensitization of the angiotensin II type 1A receptor elucidated by diacylglycerol dynamics. | Q40226288 | ||
| Atrial natriuretic factor: Its (patho)physiological significance in humans | Q42599434 | ||
| Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. | Q42616224 | ||
| The Role of Neprilysin Inhibitors in Cardiovascular Disease | Q42700358 | ||
| Use of aldosterone antagonists in heart failure | Q43258043 | ||
| Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. | Q44074134 | ||
| Eplerenone in patients with systolic heart failure and mild symptoms | Q44272913 | ||
| First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers | Q44339339 | ||
| EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). | Q46414626 | ||
| Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle | Q46465736 | ||
| Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction | Q46708478 | ||
| Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial | Q46843197 | ||
| Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). | Q48640874 | ||
| Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. | Q53907769 | ||
| Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. | Q54157090 | ||
| Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure | Q54261496 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | congestive heart failure | Q19000661 |
| P304 | page(s) | 811-826 | |
| P577 | publication date | 2016-04-22 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Potential new drug treatments for congestive heart failure | |
| P478 | volume | 25 |
| Q88599261 | Drugs' development in acute heart failure: what went wrong? |
| Q38987955 | Evolving therapies for the management of chronic and acute decompensated heart failure |
| Q53545050 | Identification of porcine relaxin in plasma by liquid chromatography-high resolution mass spectrometry. |
| Q90751712 | Linoleic acid improves assembly of the CII subunit and CIII2/CIV complex of the mitochondrial oxidative phosphorylation system in heart failure |
| Q38827338 | Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure |
Search more.